FDA Approves First CAR T-Cell Therapy and Digital Health Pilot
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 30 2025
0mins
Source: NASDAQ.COM
- First CAR T-Cell Therapy: Bristol Myers Squibb's Breyanzi has received FDA approval as the first CAR T-cell therapy for marginal zone lymphoma, marking a significant breakthrough in cancer treatment that is expected to greatly enhance patient options and outcomes.
- Digital Health Innovation: The FDA has introduced TEMPO, the first digital health pilot aimed at expanding access to chronic disease technologies, which is designed to improve patient health management through technological means and could transform treatment paradigms for chronic disease patients.
- New Therapy Approval: Gamida Cell Ltd.'s Omisirge has been approved by the FDA as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia, which is expected to provide new treatment hope for this specific patient group and improve their quality of life.
- Non-Profit Gene Therapy: Fondazione Telethon's Waskyra has received FDA approval as the first cell-based gene therapy for Wiskott-Aldrich syndrome, highlighting the innovative capabilities of non-profit organizations in the biopharmaceutical sector and potentially encouraging more non-profits to engage in related research.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like BMY with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on BMY
Wall Street analysts forecast BMY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BMY is 55.86 USD with a low forecast of 37.00 USD and a high forecast of 68.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
8 Buy
11 Hold
1 Sell
Moderate Buy
Current: 54.620
Low
37.00
Averages
55.86
High
68.00
Current: 54.620
Low
37.00
Averages
55.86
High
68.00
About BMY
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its growth portfolio includes Opdivo (nivolumab), Opdivo Qvantig (nivolumab and hyaluronidase-nvhy), Yervoy (ipilimumab), Reblozyl (luspatercept-aamt), Opdualag (nivolumab and relatlimab-rmbw), Breyanzi (lisocabtagene maraleucel), Camzyos (mavacamten), Zeposia (ozanimod), Abecma (idecabtagene vicleucel), and Sotyktu (deucravacitinib). Its other growth products include Onureg, Inrebic, and Empliciti. Its legacy portfolio includes Eliquis (apixaban), Revlimid (lenalidomide), Pomalyst/Imnovid (pomalidomide), Sprycel (dasatinib), and Abraxane (paclitaxel albumin-bound particles for injectable suspension). Opdivo (nivolumab) is a fully human monoclonal antibody that binds to the PD-1 on T and NKT cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Trump Administration Launches Medicare Drug Price Negotiations
- Expansion of Drug Negotiations: The Trump administration has expanded Medicare drug price negotiations to include treatments administered in doctors' offices for conditions such as diabetes and HIV, affecting 15 drugs set to take effect in 2028, aiming to reduce out-of-pocket costs for beneficiaries.
- Spending Overview: According to the Centers for Medicare and Medicaid Services, approximately 1.8 million beneficiaries utilized these medications between 2024 and 2025, accounting for about $27 billion in spending, highlighting the significance of Medicare expenditures in drug price negotiations.
- Pharmaceutical Impact Assessment: Analysts indicate that for 14 of the drugs, only Gilead's Biktarvy significantly impacts the company's estimated 2027 global sales, representing around 8%, while other drugs' Medicare revenue exposure is limited to 0% to 3%, suggesting minimal overall revenue impact for pharmaceutical companies.
- Kaiser Settlement on Fraud: Kaiser Permanente has agreed to a historic $556 million settlement over Medicare Advantage fraud allegations, reflecting the government's stringent enforcement stance on Medicare fraud, which could have far-reaching implications for the industry.
Continue Reading
Wall Street Analysts Adjust Ratings
- Analyst Rating Updates: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives on their outlooks, which could influence investor decisions.
- Market Reaction Insight: While specific rating changes are not detailed, analysts' opinions typically have a direct impact on stock prices, prompting investors to closely monitor these shifts.
- Investor Guidance: When considering the purchase of GM stock, analysts' insights may provide crucial reference points, aiding investors in making more informed investment choices.
- Source of Rating Changes: Comprehensive information on all analyst rating changes can be found on the analyst ratings page, ensuring investors stay updated with the latest market insights.
Continue Reading